Physician profile
Sean Harris
NPI 1457465213
$2,245.56
in general payments reported to CMS, 2019-2025
24 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $123 · 2022: $231 · 2023: $215 · 2024: $324 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.06 |
| Education | $194.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $324.26 | 2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $301.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $237.83 | 2019-2025 | Breztri |
| Teva Pharmaceuticals USA, INC. | $198.89 | 2019-2020 | |
| Medtronic, INC. | $194.03 | 2024 | |
| Dexcom, INC. | $151.39 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $109.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $109.64 | 2019-2022 | |
| Pfizer INC. | $77.65 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.90 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $70.00 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $61.86 | 2022-2025 | Trelegy Ellipta |
| Amgen INC. | $58.52 | 2019-2025 | Repatha, Otezla |
| Abbott Laboratories | $41.11 | 2022 | |
| Fortovia Therapeutics, INC. | $37.74 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.94 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $27.39 | 2019-2023 | Xarelto |
| Gilead Sciences, INC. | $27.27 | 2025 | |
| Shield Therapeutics INC | $26.90 | 2022-2023 | Accrufer |
| Astellas Pharma US INC | $17.48 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.36 | 2025 | Opsumit, Uptravi |
| Sanofi Pasteur INC. | $16.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.19 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.